Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background/aims Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver with inflammation of small and middle-sized bile ducts. Serum lipids are frequently elevated, but the use of a lipid lowering drug therapy in PBC is still a matter of debate. Application of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in hypercholesterolemic PBC patients was therefore the subject of the present study. Methods Six female patients (aged 46.5 (32-61) years; median (range)) were treated with the HMG-CoA reductase inhibitor simvastatin (5 or 20 mg/day). Levels of serum total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were determined prior to and after 2 months of treatment. Concentrations of serum markers of cholestasis, antimitochondrial antibodies (AMA), and immunoglobulins A, G and M were also assessed. Results Simvastatin significantly (P Conclusions The lipid lowering potency of the HMG-CoA reductase inhibitor simvastatin was confirmed in hypercholesterolemic patients with PBC. The drug might also prove useful as modulator of cholestasis and of immune response in this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Symposium: Advances in Liver Pathology [Abridged]: Primary Biliary Cirrhosis
Scheuer, P. J. (1967) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576706001205 · Cited by 557
Celaya, F. B. (1989) · Anales de Medicina Interna · Cited by 508
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444 · cited 1×
“Immunosuppressive properties of HMG-CoA-reductase inhibitors have been reported recently including findings from both in vitro experiments [21,22], as well as observations made in vivo in animal models [23] or in human studies [24,25].”
BackgroundInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Primary Biliary Cirrhosis: A Model Autoimmune Disease
JAMES, S. P., HOOFNAGLE, J. H., STROBER, W., & JONES, E. A. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-4-500 · Cited by 215
Tobert, J. A., Bell, G. D., Birtwell, J., James, I., Kukovetz, W. R., Pryor, J. S., Buntinx, A., Holmes, I. B., Chao, Y. S., & Bolognese, J. A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110530 · Cited by 202
Jahn, C. E., Schaefer, E. J., Taam, L., Hoofnagle, J. H., Lindgren, F. T., Albers, J. J., Jones, E. A., & Brewer, H. B. (1985) · PubMed · Cited by 166
Lipoprotein abnormalities in primary biliary cirrhosis
Jahn, C. E., Schaefer, E. J., Taam, L., Hoofnagle, J. H., Lindgren, F. T., Albers, J. J., Jones, E. A., & Brewer, H. B. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90642-0 · Cited by 152
Cited by
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Abraldes, J. G., Albillos, A., Bañares, R., Turnes, J., González, R., García–Pagán, J. C., & Bosch, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.043 · Cited by 471
Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., Krause, R., Lammert, F., Langner, C., Zatloukal, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.009 · Cited by 468
Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology · doi:10.1002/hep.20784 · Cited by 355
Metadata
- Authors
- Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
- Corresponding author
- Leonhardt, Urs
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 36
- Issue
- 4
- Pages
- 454-458
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1969611494
- Cited by
- 94
- References
- 32
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2022: 2 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 6 · 2012: 3
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, primary biliary cirrhosis, statins, serum lipids, hypercholesterolemia, LDL cholesterol, HDL cholesterol, total cholesterol, alkaline phosphatase, gamma-glutamyl transferase, antimitochondrial antibodies, immunoglobulin M, immunoglobulins, lipid-lowering therapy
- MeSH terms
- Adult, Alkaline Phosphatase, Hypolipidemic Agents, Cholesterol, Female, gamma-Glutamyltransferase, Humans, Immunoglobulin M, Lipids, Cholesterol, LDL, Liver Cirrhosis, Biliary, Middle Aged, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. https://app.cochat.ai/papers/10.1016/s0168-8278(02)00006-5
- The paper
- Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G. (2002). Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(02)00006-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.